Blood cytokines as biomarkers of in vivo toxicity in preclinical safety assessment: considerations for their use.
about
Toll-like receptor agonist augments virus-like particle-mediated protection from Ebola virus with transient immune activation.Inflammatory profiles in canine intervertebral disc degenerationImpact of TNF-α (rs1800629) and IL-6 (rs1800795) Polymorphisms on Cognitive Impairment in Asian Breast Cancer Patients.Psychoneuroimmunological relationships in women with fibromyalgiaThe current status of biomarkers for predicting toxicity.Translational immunologic safety evaluation: a perspective.Development of blood biomarkers for drug-induced liver injury: an evaluation of their potential for risk assessment and diagnostics.Cytokines in ovarian folliculogenesis, oocyte maturation and luteinisation.Scientific and Regulatory Policy Committee Points-to-consider Paper*: Drug-induced Vascular Injury Associated with Nonsmall Molecule Therapeutics in Preclinical Development: Part 2. Antisense Oligonucleotides.Scientific and Regulatory Policy Committee Points-to-consider Paper*: Drug-induced Vascular Injury Associated with Nonsmall Molecule Therapeutics in Preclinical Development: Part I. Biotherapeutics.Blood-borne biomarkers and bioindicators for linking exposure to health effects in environmental health science.Taxonomic applicability of inflammatory cytokines in adverse outcome pathway (AOP) development.Cytokines: The Good, the Bad, and the Deadly.Inflammatory response to surgical trauma in patients with minilaparotomy cholecystectomy versus laparoscopic cholecystectomy: a randomised multicentre study.Exposure to ozone induces a systemic inflammatory response: possible source of the neurological alterations induced by this gas.Cytokine genes as potential biomarkers for muscle weakness in OPMD.IL-4 Protects the Mitochondria Against TNFα and IFNγ Induced Insult During Clearance of Infection with Citrobacter rodentium and Escherichia coli.High systemic IL-6 is associated with worse prognosis in patients with non-small cell lung cancer.Materials design at the interface of nanoparticles and innate immunity.DNA Methylation Events as Markers for Diagnosis and Management of Acute Myeloid Leukemia and Myelodysplastic Syndrome.Toxicity profile of small-molecule IAP antagonist GDC-0152 is linked to TNF-α pharmacology.Cytokines associated with increased erythropoiesis in Sprague-Dawley rats administered a novel hyperglycosylated analog of recombinant human erythropoietin.Changes in serum cytokine levels, hepatic and intestinal morphology in aflatoxin B1-induced injury: modulatory roles of melatonin and flavonoid-rich fractions from Chromolena odorata.Levels of circulating cortisol and cytokines in members of the Canadian Armed Forces: Associations with age, sex and anthropometry.Remote intermittent ischemia before coronary artery bypass graft surgery: a strategy to reduce injury and inflammation?Heparin and EDTA anticoagulants differentially affect the plasma cytokine levels in humans.Assessment of the performance of three multiplex array panels for the detection of circulating cytokines and chemokines in naive, LPS, and SEB-treated cynomolgus macaques.Advantage of a Narrow Spectrum Host Defense (Antimicrobial) Peptide Over a Broad Spectrum Analog in Preclinical Drug DevelopmentModels of Drug Induced Liver Injury (DILI) - Current Issues and Future Perspectives
P2860
Q31152190-022E64F7-70FA-470E-AB78-6E14200152DFQ35891874-202BF55B-8DCA-44FE-B1CC-F09216139476Q36152838-BF3D978D-1ECA-4A70-89F1-4B249621DB5AQ37043523-B6AA80FE-57E1-473A-A69F-66BE3FF846A4Q37408227-3E589673-3B1A-4E29-B681-E94462AE2C8CQ38042463-8E0DD6BB-C150-476E-8080-5D69A3D9CEACQ38122649-3F5F45EA-D1D9-4A1F-9CA9-1CD787D09A9BQ38165903-DDFC94F5-0DAC-4868-A459-325035679279Q38365365-55C31FBE-4D6E-4B0E-9C97-81F0295CE6D7Q38365744-41021A28-E4E3-4A3E-AF07-10DD66AFD383Q38809034-34501313-D732-4FD9-8C39-7548245383EFQ38903488-D98366D9-2FD8-4B45-B1E3-5BD8EE686817Q39002175-393662D3-57AF-4220-AAC1-0686B5E5F005Q40116274-6E319CCF-CCA2-40A2-A783-85D00965DC1DQ40204746-226CB35C-3F99-4DC1-89E4-AA4E366E6C89Q40629006-74336DBB-3885-409B-B4EF-91ACE4F0FA10Q40946004-3A5315F1-AD11-4813-9C87-AD6532E80D68Q41034849-74326B80-6362-4D99-859F-8A090EF59C44Q41915826-85545288-7617-4316-B236-09CC2F1CEA91Q42361215-586DAE67-A93B-4101-B08E-EC51E8784DEBQ42716028-940E85E5-9A60-4697-A89B-1BBEE8AC0436Q43748919-EC1A2332-5B6C-4F37-B11A-67733C210B21Q46826866-838C6129-B32A-45CE-8A8F-DA3DD63D7D57Q47335964-45F964D2-CBD6-4BEB-A919-FF7B3BA69E5CQ48266257-43EE1C65-26E2-4FEB-B57D-57AF56E36A33Q50902383-9C57514E-F400-4847-9627-932ADE5B7AFFQ53677255-F0C876F6-0DDF-4A70-B381-5A440FAD5F6FQ58728409-B54ACB52-B1E4-4B2A-B38E-7922365F7D64Q58804131-E2447C99-720F-4386-A922-3CDA4249E8E0
P2860
Blood cytokines as biomarkers of in vivo toxicity in preclinical safety assessment: considerations for their use.
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Blood cytokines as biomarkers ...... considerations for their use.
@ast
Blood cytokines as biomarkers ...... considerations for their use.
@en
Blood cytokines as biomarkers ...... considerations for their use.
@nl
type
label
Blood cytokines as biomarkers ...... considerations for their use.
@ast
Blood cytokines as biomarkers ...... considerations for their use.
@en
Blood cytokines as biomarkers ...... considerations for their use.
@nl
prefLabel
Blood cytokines as biomarkers ...... considerations for their use.
@ast
Blood cytokines as biomarkers ...... considerations for their use.
@en
Blood cytokines as biomarkers ...... considerations for their use.
@nl
P2860
P921
P356
P1476
Blood cytokines as biomarkers ...... considerations for their use.
@en
P2093
Jacqueline M Tarrant
P2860
P356
10.1093/TOXSCI/KFQ134
P577
2010-05-06T00:00:00Z
2010-09-01T00:00:00Z